ATRC / AtriCure: Despite Reasonable Top-Line Growth, No Change To Hold Thesis

AtriCure, Inc. (NASDAQ:ATRC ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych – Gilmartin Group, Inve more_horizontal

Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth con more_horizontal

While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended June 2023, it could be wort more_horizontal

AtriCure, Inc. (NASDAQ:ATRC ) Q2 2023 Earnings Conference Call July 25, 2023 4:30 PM ET Company Participants Marissa Bych - Vice President-Gilmartin G more_horizontal

AtriCure (ATRC) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0. more_horizontal

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), more_horizontal

AtriCure, Inc. has seen continued momentum in Afib and related markets. The company sees solid revenue growth, which, amidst a retreat in the share pr more_horizontal

AtriCure, Inc. (NASDAQ:ATRC ) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ET Company Participants Marissa Bych – Vice President-Gilmartin G more_horizontal